# Safety and Efficacy of the Bispecific T-Cell Engager (BiTE) in Kidney Transplant Recipients With Chronic Active Antibody-Mediated Rejection

> **NCT07689578** · PHASE4 · RECRUITING · sponsor: **Turun Song** · enrollment: 50 (estimated)

## Conditions studied

- Antibody Mediated Rejection After Kidney Transplantation

## Interventions

- **DRUG:** BiTE (BCMA x CD3 Bispecific Antibody)

## Key facts

- **NCT ID:** NCT07689578
- **Lead sponsor:** Turun Song
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-30
- **Primary completion:** 2029-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07689578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07689578, "Safety and Efficacy of the Bispecific T-Cell Engager (BiTE) in Kidney Transplant Recipients With Chronic Active Antibody-Mediated Rejection". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07689578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*